Clinical and palliative care outcomes for melanoma patients treated with anti-PD1 https://t.co/C57XbNxglf We found that people with poor performance status did poorly and more likely to die in hospital #anzspm2022
RT @DrPeterLau: @drcbsteer @anmwongNZ showed similarly poor outcomes for patients with ECOG 2/3 performance status treated with anti-PD1 mo…
@drcbsteer @anmwongNZ showed similarly poor outcomes for patients with ECOG 2/3 performance status treated with anti-PD1 monotherapy several years ago. https://t.co/G7ohlLBFJQ. Same finding now just with combo
RT @fischmd: @ramsedhom @tmprowell @IshwariaMD @mtmdphd @montypal @oncology_bg @guptaarjun90 Poor performance status is associated with wor…
RT @fischmd: @ramsedhom @tmprowell @IshwariaMD @mtmdphd @montypal @oncology_bg @guptaarjun90 Poor performance status is associated with wor…
RT @fischmd: @ramsedhom @tmprowell @IshwariaMD @mtmdphd @montypal @oncology_bg @guptaarjun90 Poor performance status is associated with wor…
RT @fischmd: @ramsedhom @tmprowell @IshwariaMD @mtmdphd @montypal @oncology_bg @guptaarjun90 Poor performance status is associated with wor…
RT @fischmd: @ramsedhom @tmprowell @IshwariaMD @mtmdphd @montypal @oncology_bg @guptaarjun90 Poor performance status is associated with wor…
@ramsedhom @tmprowell @IshwariaMD @mtmdphd @montypal @oncology_bg @guptaarjun90 Poor performance status is associated with worse patient outcomes with #ImmunoOnc therapy. Here are two relevant papers: @KartikSehgal_MD https://t.co/vvpMEoBmam @anmwongNZ ht
In pts w PS 2, 13.6% G3/4 tox and OS 2.4 months. Similar to our previous findings. Good to have this data when discussing w pts/setting expectations https://t.co/HW98USIAVq
RT @sonialf: #anzspm18 Here it is.... clinical and #palliative outcomes of melanoma patients treated with PD1 inhibitors https://t.co/AOpI…
RT @sonialf: #anzspm18 Here it is.... clinical and #palliative outcomes of melanoma patients treated with PD1 inhibitors https://t.co/AOpI…
RT @sonialf: #anzspm18 @anmwongNZ got a bit shout out from Dr Matteo Carlino at the @ANZSPM conference right now! https://t.co/AOpII6omNi
RT @sonialf: #anzspm18 @anmwongNZ got a bit shout out from Dr Matteo Carlino at the @ANZSPM conference right now! https://t.co/AOpII6omNi
RT @sonialf: #anzspm18 Here it is.... clinical and #palliative outcomes of melanoma patients treated with PD1 inhibitors https://t.co/AOpI…
RT @meera_agar: Impact of ECOG on anti-PD1 treatments #anzspm18 https://t.co/bAdBlvIly5
#anzspm18 @anmwongNZ got a bit shout out from Dr Matteo Carlino at the @ANZSPM conference right now! https://t.co/AOpII6omNi
#anzspm18 Here it is.... clinical and #palliative outcomes of melanoma patients treated with PD1 inhibitors https://t.co/AOpII6omNi
Impact of ECOG on anti-PD1 treatments #anzspm18 https://t.co/bAdBlvIly5
RT @fischmd: @THilalMD @NicoleKuderer @gary_lyman @rsm2800 In melanoma, patients with poor baseline ECOG PS have a significantly lower surv…
@NicoleKuderer @THilalMD @SWOG @fischmd @ArunAR101 & I have something in review. But let me share another article for now: https://t.co/NJYOCvO8dS
Think about this when using anti-PD1 therapy. Although not traditional chemo, it’s not benign. #immunotherapy #oncology https://t.co/R0BJJXy53l
@THilalMD @NicoleKuderer @gary_lyman @rsm2800 In melanoma, patients with poor baseline ECOG PS have a significantly lower survival and reduced response to anti-PD1, see https://t.co/8zmWt5ZCoN
@notahedge It is entirely appropriate to have a discussion about resource use and likely trajectory of a patients disease. Two papers are informative in this setting Wong et al - poor PS --> unlikely to respond to IO in melanoma (https://t.co/6KardApb
Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death-1 monoclonal antibodies for advanced melanoma. https://t.co/eAT35gobrP
RT @fischmd Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma https://t.co/cl2wll4oZ3
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @sandrineaspesla: very important message: immunotherapy is not meant for patients with bad performance status https://t.co/Cy7HuaU9mi
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @LindaMileshkin: Well done on an important paper to help us discuss immunotherapy outcomes with pts @anmwongNZ @Prof_G_McArthur https://…
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @sandrineaspesla: very important message: immunotherapy is not meant for patients with bad performance status https://t.co/Cy7HuaU9mi
RT @sandrineaspesla: very important message: immunotherapy is not meant for patients with bad performance status https://t.co/Cy7HuaU9mi
RT @sandrineaspesla: very important message: immunotherapy is not meant for patients with bad performance status https://t.co/Cy7HuaU9mi
RT @sandrineaspesla: very important message: immunotherapy is not meant for patients with bad performance status https://t.co/Cy7HuaU9mi
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @sandrineaspesla: very important message: immunotherapy is not meant for patients with bad performance status https://t.co/Cy7HuaU9mi
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @sandrineaspesla: very important message: immunotherapy is not meant for patients with bad performance status https://t.co/Cy7HuaU9mi
very important message: immunotherapy is not meant for patients with bad performance status https://t.co/Cy7HuaU9mi
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @LindaMileshkin: Well done on an important paper to help us discuss immunotherapy outcomes with pts @anmwongNZ @Prof_G_McArthur https://…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @anmwongNZ: @ChandlerParkMD @JackWestMD This is in the paper. Here's the link for the paper - https://t.co/HW98USIAVq https://t.co/yQtdK…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
@jasonlukemd Agree, important to look at other prognostic factors. Here's the link to the paper. https://t.co/y45AFc7sLo https://t.co/emohixQ423
Great work by @anmwongNZ https://t.co/Ey9FiRD8L5
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
Interesante cuestión. Diferencias desde los ensayos a la práctica clínica https://t.co/7TrsRhClGN
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
@ChandlerParkMD @JackWestMD This is in the paper. Here's the link for the paper - https://t.co/HW98USIAVq https://t.co/yQtdKAC2CX
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
I can think of SOOOO many Oncologists who will completely ignore this data and give dying patients futile treatment. https://t.co/XMeICyq61I
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
Discussing this in journal club this morning - limited benefit in immunotherapy in poor PS pts despite less toxicity https://t.co/O1GLSbvUw7
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @JackWestMD: IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse…
IMPORTANT. We can't generalize & presume immunotherapy in fit pts on trials is as effective in pts w/poor PS, likely worse immune fxn. https://t.co/aq5FVaUFvT
RT @scserendipity1: Small retrospective study but important and thought provoking. Just because we can doesn't we should. More research in…
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @scserendipity1: Small retrospective study but important and thought provoking. Just because we can doesn't we should. More research in…
Small retrospective study but important and thought provoking. Just because we can doesn't we should. More research in this group of pts https://t.co/sJesc15qnG
RT @RielyMD: Wow https://t.co/kefkEtFxSO